FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL					
DMB Number:	3235-0287				
Estimated average burden					
ours per respons	e 0.5				

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	es)													
Name and Address of Reporting Person * Cope Frederick O				2. Issuer Name and Ticker or Trading Symbol NAVIDEA BIOPHARMACEUTICALS, INC. [NAVB]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X Officer (give title below) Other (specify below)					
(Last) (First) (Middle) 5600 BLAZER PARKWAY, SUITE 200				3. Date of Earliest Transaction (Month/Day/Year) 03/10/2014								SVP			
(Street)				4. If Amendment, Date Original Filed(Month/Day/Year)							6. Individual or Joint/Group Filing(Check Applicable Line) X_Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	OH 4301	(State)	(Zip)												
		(5.2.13)			Tab			1					Beneficially		
1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		f Code (Instr. 8)		(A) or Disposed of (D) (Instr. 3, 4 and 5)		1 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		Following (s)	Form: Direct (D)	7. Nature of Indirect Beneficial Ownership			
					Code	V	Amount (A) or Price			or Indirect (I) (Instr. 4)		(Instr. 4)			
Common	Stock		03/10/2014			S(1)		15,000	D	\$ 1.96	75,814			D	
Common	Stock										8,637			I	By 401(k)
Reminder: I	Report on a	separate line fo	or each class of secu	rities beneficia	lly o	wned direc	ctly o	r							
							cont	ained i	n this fo	orm ar	e not req	uired to re	formation spond unl itrol numb	ess	EC 1474 (9- 02)
				Derivative Secu 2.g., puts, calls,								1			
Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/\)	Execution Da any	4. Transact Code Year) (Instr. 8)	ion	of	and Expiration Date (Month/Day/Year) Ar Un Set (In 4)		Am Und Sec (Ins	Citle and count of derlying urities str. 3 and	8. Price of Derivative Security (Instr. 5) Beneficial Owned Following Reported Transactic (Instr. 4)		Ownership Form of Derivative Security: Direct (D) or Indirect	Beneficial Ownership (Instr. 4) D)	
				Code	V	(A) (D)	Date Exe	e rcisable	Expiration Date	On Titl	or Number of Shares				

Reporting Owners

Reporting Owner Name / Address	Relationships						
Reporting Owner Name / Address		10% Owner	Officer	Other			
Cope Frederick O 5600 BLAZER PARKWAY SUITE 200 DUBLIN, OH 43017			SVP				

Signatures

William J. Kelly, Jr., Attorney-In-Fact	03/11/2014
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Sales were effected to generate funds required to cover tax obligations arising from expiring options or the vesting of shares of restricted stock. The transaction is matchable under Section 16(b) of the Securities Exchange Act with Dr. Cope's purchase of 3,500 shares of common stock at \$1.43 per share on November 8, 2013. As a

result, Dr. Cope will pay the company \$1,855 representing the full amount of the profit realized in connection with the short-swing transaction.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.